Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Multicenter, Retrospective Chart Review of First-time Opsumit (Macitentan) Users in the United States

Next Previous
Trial Profile

Multicenter, Retrospective Chart Review of First-time Opsumit (Macitentan) Users in the United States

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 08 Feb 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Macitentan (Primary)
  • Indications Pulmonary arterial hypertension
  • Focus Adverse reactions
  • Acronyms OrPHeUS
  • Sponsors Actelion Pharmaceuticals

    • Most Recent Events

    • 29 Aug 2022 Results assessing the demographics, clinical characteristics, safety, tolerability, and outcomes associated with initiation of the ERA macitentan and the PDE5i tadalafil in patients with comorbidities in the US OPsumit USers (OPUS) and the OPsumit Historical USers cohort (OrPHeUS) combined dataset, presented at the ESC Congress 2022 - Annual Congress of the European Society of Cardiology.
    • 19 May 2021 Real-world data from OPUS & Orpheus studies were used to describe pulmonary arterial hypertension patient characteristics and treatment patterns across four US regions, presented at the 117th International Conference of the American Thoracic Society.
    • 17 May 2021 Study insights from OPUS (NCT02126943) / ORPHEUS (NCT03197688), presented at the 70th Annual Scientific Session of the American College of Cardiology.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top